N/A N=32

Histological Characterization and Differentiation of Rash From Other Epidermal Growth Factor Receptor (EGFR) Inhibitors

Skin Rash

Bottom Line

View on ClinicalTrials.gov: NCT00709878 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Sep 2010

Primary outcome: Primary: Differences in Histologic Alterations in Rash Caused by Lapatinib, a Dual HER1/2 Inhibitor (HER1/2i), and the Single HER1 Inhibitors (HER1i) Cetuximab, Erlotinib,and Panitumumab. — 1; 1; 0; 2 Total number of cases

Study Design & Population

Study type: Observational
Phase: N/A
Interventions: Skin Biopsy of Skin Rash Secondary to EGFRI Use (Procedure)
Age: Pediatric, Adult, Older Adult
Sex: All
Sponsor: Northwestern University
Primary completion: Aug 2010

Outcome Measures

Outcome	Result	p-value
PRIMARY Differences in Histologic Alterations in Rash Caused by Lapatinib, a Dual HER1/2 Inhibitor (HER1/2i), and the Single HER1 Inhibitors (HER1i) Cetuximab, Erlotinib,and Panitumumab.	1; 1; 0; 2; 1; 2	—

Summary

The purpose of this study is to characterize the microscopic findings of skin rash associated with the use of chemotherapeutic anticancer agents known as epidermal growth factor inhibitors (EGFRIs).

Eligibility Criteria

Inclusion Criteria

Patients treated with lapatinib who developed skin toxicities and were biopsied.
Patients treated with erlotinib, cetuximab, or panitumumab who have been biopsied for skin rash.

Exclusion Criteria

Patients who do not fit above criteria.

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00709878). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.